JP5186075B2 - テクネチウム−９９ｍ及びレニウムで標識した小型作用剤及び腫瘍の画像化方法 - Google Patents

テクネチウム−９９ｍ及びレニウムで標識した小型作用剤及び腫瘍の画像化方法 Download PDF

Info

Publication number
JP5186075B2
JP5186075B2 JP2001580865A JP2001580865A JP5186075B2 JP 5186075 B2 JP5186075 B2 JP 5186075B2 JP 2001580865 A JP2001580865 A JP 2001580865A JP 2001580865 A JP2001580865 A JP 2001580865A JP 5186075 B2 JP5186075 B2 JP 5186075B2
Authority
JP
Japan
Prior art keywords
carbon atoms
compound
group
complex
technetium
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2001580865A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004501093A5 (https=
JP2004501093A (ja
Inventor
モハメド アシュファク
フリーベ マタイ
ボルザッティ クリスティーナ
ジー ジョーンズ アラン
デビソン アラン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Harvard University
Original Assignee
Harvard University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Harvard University filed Critical Harvard University
Publication of JP2004501093A publication Critical patent/JP2004501093A/ja
Publication of JP2004501093A5 publication Critical patent/JP2004501093A5/ja
Application granted granted Critical
Publication of JP5186075B2 publication Critical patent/JP5186075B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/13—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0478—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group complexes from non-cyclic ligands, e.g. EDTA, MAG3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C323/39—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton at least one of the nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom
    • C07C323/40—Y being a hydrogen or a carbon atom
    • C07C323/41—Y being a hydrogen or an acyclic carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F13/00—Compounds containing elements of Groups 7 or 17 of the Periodic Table
    • C07F13/005—Compounds without a metal-carbon linkage
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Optics & Photonics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
JP2001580865A 2000-04-28 2001-04-27 テクネチウム−９９ｍ及びレニウムで標識した小型作用剤及び腫瘍の画像化方法 Expired - Fee Related JP5186075B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US20063300P 2000-04-28 2000-04-28
US60/200,633 2000-04-28
PCT/US2001/013550 WO2001083436A2 (en) 2000-04-28 2001-04-27 Small technetium-99m and rhenium labeled agents and methods for imaging tumors

Publications (3)

Publication Number Publication Date
JP2004501093A JP2004501093A (ja) 2004-01-15
JP2004501093A5 JP2004501093A5 (https=) 2008-06-26
JP5186075B2 true JP5186075B2 (ja) 2013-04-17

Family

ID=22742530

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001580865A Expired - Fee Related JP5186075B2 (ja) 2000-04-28 2001-04-27 テクネチウム−９９ｍ及びレニウムで標識した小型作用剤及び腫瘍の画像化方法

Country Status (8)

Country Link
US (2) US7321027B2 (https=)
EP (1) EP1276718B1 (https=)
JP (1) JP5186075B2 (https=)
AT (1) ATE359998T1 (https=)
AU (2) AU6968301A (https=)
CA (1) CA2407592C (https=)
DE (1) DE60127951T2 (https=)
WO (1) WO2001083436A2 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2400856C (en) * 2000-02-22 2011-03-29 Biostream Therapeutics, Inc. Imaging agents for diagnosis of parkinson's disease
JP4796301B2 (ja) * 2002-11-08 2011-10-19 プレジデント アンド フェロウズ オブ ハーバード カレッジ テクネチウム−９９ｍ及びレニウムで標識した小型作用剤及び組織、臓器及び腫瘍の画像化方法
JP2009051784A (ja) * 2007-08-28 2009-03-12 Inst Nuclear Energy Research Rocaec 癌を抑制する放射性物質及びその調整方法
AU2010259862A1 (en) * 2009-06-13 2012-02-02 President And Fellows Of Harvard College Compositions and methods for imaging tissues, organs and tumors
WO2015191505A1 (en) * 2014-06-09 2015-12-17 Los Alamos National Security, Llc Polydentate ligands and their complexes for molecular catalysis
US10550139B2 (en) 2014-06-09 2020-02-04 Triad National Security, Llc Polydentate ligands and their complexes for molecular catalysis
EP3160514B1 (en) 2014-06-27 2024-07-31 Reiley Pharmaceuticals, Inc. Conjugates derived from non-steroidal anti-inflammatory drugs and methods of use thereof in imaging
US10053478B2 (en) 2015-01-09 2018-08-21 Reiley Pharmaceuticals, Inc. COX-2-targeting, platinum-containing conjugates and their use in the treatment of tumors and cancers
EP3328372A4 (en) 2015-07-28 2019-03-20 University Of Iowa Research Foundation COMPOSITIONS AND METHOD FOR THE TREATMENT OF CANCER
AU2017281940C1 (en) 2016-06-24 2024-11-07 University Of Iowa Research Foundation Compositions and methods of treating melanoma
WO2017223428A1 (en) 2016-06-24 2017-12-28 Cornell University Rhenium complexes and methods of use for treating cancer
US10487100B1 (en) 2017-04-04 2019-11-26 Triad National Security, Llc Macrocyclic ligands and their complexes for bifunctional molecular catalysis
US11529335B2 (en) 2020-07-31 2022-12-20 University Of Iowa Research Foundation Compositions and methods for treating cancer
WO2023009442A1 (en) * 2021-07-26 2023-02-02 Rapid Therapeutic Sciences Laboratories, Inc. Improved process for ph-balanced cbg (# 10)
CN120647688A (zh) * 2024-03-15 2025-09-16 中国科学院上海药物研究所 一种黑色素瘤靶向的放射性药物及其制备与应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA852981B (en) * 1984-04-30 1985-11-27 Univ Johns Hopkins Brain imaging radiopharmaceuticals
US4638051A (en) * 1984-04-30 1987-01-20 The Johns Hopkins University Brain imaging radiopharmaceuticals
US5136038A (en) * 1984-07-19 1992-08-04 University Of Florida Radiopharmaceuticals and chelating agents useful in their preparation
EP0200211A1 (en) * 1985-05-01 1986-11-05 The Research Foundation Of State University Of New York Diagnostic radiopharmaceutical compounds
JPH02180865A (ja) * 1987-12-29 1990-07-13 Nippon Mejifuijitsukusu Kk キレート形成性化合物とその用途
EP0381713B1 (en) * 1988-04-29 1994-01-19 Mallinckrodt, Inc. Diaminedithiol chelating agents for radiopharmaceuticals
US5919934A (en) * 1997-02-19 1999-07-06 The George Washington University Compounds, compositions, and methods for cancer imaging and therapy

Also Published As

Publication number Publication date
WO2001083436A2 (en) 2001-11-08
DE60127951T2 (de) 2008-01-17
DE60127951D1 (de) 2007-05-31
EP1276718B1 (en) 2007-04-18
US20080226550A1 (en) 2008-09-18
CA2407592A1 (en) 2001-11-08
JP2004501093A (ja) 2004-01-15
US7321027B2 (en) 2008-01-22
WO2001083436A3 (en) 2002-06-20
AU6968301A (en) 2001-11-12
CA2407592C (en) 2011-03-22
US20040097735A1 (en) 2004-05-20
ATE359998T1 (de) 2007-05-15
EP1276718A2 (en) 2003-01-22
AU2001269683B2 (en) 2006-12-21

Similar Documents

Publication Publication Date Title
US20080226550A1 (en) Small technetium-99m and rhenium labeled agents and methods for imaging tumors
ES2700234T3 (es) Inhibidores marcados del antígeno de membrana específico de la próstata (PSMA), evaluación biológica y uso como agentes para la obtención de imágenes
AU2001269683A1 (en) Small technetium-99m and rhenium labeled agents and methods for imaging tumors
Friebe et al. [99mTc] oxotechnetium (V) complexes of amine-amide-dithiol chelates with dialkylaminoalkyl substituents as potential diagnostic probes for malignant melanoma
JP4796301B2 (ja) テクネチウム−９９ｍ及びレニウムで標識した小型作用剤及び組織、臓器及び腫瘍の画像化方法
US5919934A (en) Compounds, compositions, and methods for cancer imaging and therapy
Chaudhary et al. Design, development and bio-evaluation of a novel radio-ligand 99mTc-THQ-DTPA as a sigma 2 receptor specific breast tumor imaging agent
AU2015203742B2 (en) Labeled inhibitors of prostate specific membrane antigen (psma), biological evaluation, and use as imaging agents
León et al. Novel mixed ligand technetium complexes as 5-HT1A receptor imaging agents
US8747810B2 (en) Compositions and methods for imaging tissues, organs and tumors
Gniazdowska et al. Synthesis, radiochemistry and stability of the conjugates of technetium-99m complexes with Substance P
Kraemer et al. Matthias Friebe, Ashfaq Mahmood,*, Cristina Bolzati, Antje Drews, Bernd Johannsen, Michael Eisenhut,||
HK1215249B (en) Labeled inhibitors of prostate-specific membrane antigen (psma), biological evaluation, and use as imaging agents

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080428

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20080428

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20110126

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110201

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110412

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110419

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110801

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120313

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120612

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120619

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120912

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20121225

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20130121

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20160125

Year of fee payment: 3

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees